Patents by Inventor James E. Fritz
James E. Fritz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6693199Abstract: A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: GrantFiled: November 21, 2002Date of Patent: February 17, 2004Assignee: Agouron Pharmaceuticals, Inc.Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
-
Publication number: 20030216569Abstract: A method of making HIV protease inhibitors of general formula (1): 1Type: ApplicationFiled: November 21, 2002Publication date: November 20, 2003Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
-
Patent number: 6525215Abstract: Compounds useful as intermediates in the preparation of HIV protease inhibitors.Type: GrantFiled: June 21, 2001Date of Patent: February 25, 2003Assignee: Agouron Pharmaceuticals, Inc.Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
-
Publication number: 20020077338Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: ApplicationFiled: June 21, 2001Publication date: June 20, 2002Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
-
Patent number: 6358994Abstract: This invention provides compounds of the Formula I: which are useful as tachykinin receptor antagonists. This invention also provides methods employing these compounds, as well as pharmaceutical formulations comprising these compounds.Type: GrantFiled: January 27, 2000Date of Patent: March 19, 2002Assignee: Eli Lilly and CompanyInventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
-
Patent number: 6339094Abstract: This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.Type: GrantFiled: January 27, 2000Date of Patent: January 15, 2002Assignee: Eli Lilly and CompanyInventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
-
Patent number: 6311621Abstract: A shock-resistant electronic circuit assembly (10) is provided in which an electronic circuit is encased in an encapsulation (14) that engages a surrounding enclosure (18) in shock-dispersing contact therewith. The encapsulation may have a plurality of edges (16, 16a, 16b), fins (24) or bosses (70) that bear against the enclosure. The encapsulation may include a shock-absorbing material (14f) disposed against the enclosure to protect the circuit against vibrations and a structural support material such as a casing (14e) to protect the circuit against stress. The circuit assembly (10) may be part of a sheathed initiator assembly (55) that includes a transfer member (58) for converting shock wave energy into electrical energy for the electronic circuit, and the released energy may be converted into a detonation initiation signal. Assembly (55) may be part of a detonator (100) that receives a non-electric initiation signal and detonates following the delay determined by the electronic circuit.Type: GrantFiled: December 6, 1999Date of Patent: November 6, 2001Assignee: The Ensign-Bickford CompanyInventors: Paul N. Marshall, Thomas C. Tseka, Brendan M. Walsh, James E. Fritz
-
Patent number: 6271235Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: GrantFiled: June 7, 1995Date of Patent: August 7, 2001Assignee: Agouron Pharmaceuticals, Inc.Inventors: Bruce A. Dressman, James E. Fritz, Stephen W. Kaldor, Vincent J. Kalish, Siegfried Heinz Reich, Michael J. Rodriguez, Timothy A. Shepherd, John H. Tatlock, Louis Nickolaus Jungheim
-
Patent number: 6162812Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: GrantFiled: April 1, 1999Date of Patent: December 19, 2000Assignee: Agouron Pharmaceuticals, Inc.Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
-
Patent number: 6126932Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula ##STR1## where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associated disorders.Type: GrantFiled: October 12, 1999Date of Patent: October 3, 2000Assignee: Eli Lilly and CompanyInventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
-
Patent number: 6125762Abstract: A flat-form separation device (12) is made of two half-section members (22, 22') which are fastened together by a series of fasteners (38) to define therebetween a receiving channel within which an expansion device (40) is received. Aside from the receiving channel and any apertures which are to receive mechanical fasteners, the separation device (12) is solid throughout and free of other channels or cavities. The device (12) includes a pair of joinder flanges formed by mating half-flange segments (28a and 28b), which contain apertures (32 and 34) by which the flat-form separation device (12) may be secured to structures (48, 50) which are to be temporarily joined by the device (12). Because of the cross-sectional profile of the half-section members (22, 22'), they may be made by manufacturing techniques, such as machining, which enable the use of alloys or metals which are much tougher and stronger than those which can be extraded to form prior art hollow-form separation devices (14).Type: GrantFiled: June 30, 1998Date of Patent: October 3, 2000Assignee: The Ensign-Bickford CompanyInventors: James E. Fritz, Steven L. Olson, Jon E. Rydberg
-
Patent number: 6079332Abstract: A shock-resistant electronic circuit assembly (10) is provided in which an electronic circuit is encased in an encapsulation (14) that engages a surrounding enclosure (18, 22) in shock-dispersing contact therewith. The encapsulation may have a plurality of edges (16, 16a, 16b), fins (24) or bosses (70) that bear against the enclosure. The encapsulation may include a shock-absorbing material (14f) disposed against the enclosure to protect the circuit against vibrations and a structural support material (14e) to protect the circuit against stress. The circuit assembly (10) may contain a capacitor (34) for storing an electrical signal and timing circuitry for releasing the stored energy after a predetermined delay. The circuit assembly (10) may be part of a transducer-circuit assembly (55) that includes a transducer module (58) for converting shock wave energy into electrical energy for the electronic circuit, and the released energy may be converted into a detonation initiation signal.Type: GrantFiled: November 1, 1996Date of Patent: June 27, 2000Assignee: The Ensign-Bickford CompanyInventors: Paul N. Marshall, Thomas C. Tseka, Brendan M. Walsh, James E. Fritz
-
Patent number: 6060484Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.Type: GrantFiled: January 6, 1999Date of Patent: May 9, 2000Assignee: Eli Lilly and CompanyInventors: James E. Fritz, Stephen W. Kaldor, Jeffrey A. Kyle, John E. Munroe
-
Patent number: 6021715Abstract: A manifold (130) is configured to have a body portion (131) having at least one initiation port (132) for receiving an initiation device and at least one tapered boss (138) mounted on the body portion (131). The boss (138) has an elliptical cross-sectional configuration and a boss bore (140) for receiving a fuse or linear explosive charge (16) and it communicates with the initiation port (132). There is a clamp member (160) having an aperture (164) dimensioned and configured to generally conform to the boss (138), and tension means such as a set of bolts (166) for urging the clamp member (160) towards the manifold (130). There may be a bushing material (121) on the boss. The manifold (130) may be coupled to a separation device (23) that includes a frangible joint (24) through which is disposed an expansion member (110).Type: GrantFiled: March 31, 1998Date of Patent: February 8, 2000Assignee: The Ensign-Bickford CompanyInventors: James E. Fritz, John A. Graham, Jon E. Rydberg, Steven L. Olson
-
Patent number: 5998630Abstract: The present invention relates to compounds used for increasing activation of the 5-HT1F receptor.Type: GrantFiled: May 21, 1999Date of Patent: December 7, 1999Assignee: Eli Lilly and CompanyInventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
-
Patent number: 5952343Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: GrantFiled: June 7, 1995Date of Patent: September 14, 1999Assignee: Agouron Pharmaceuticals, Inc.Inventors: Bruce A. Dressman, James E. Fritz, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
-
Patent number: 5942536Abstract: The invention provides novel 5-HT.sub.1f agonists of formula (I) where X, R.sup.1, R.sup.2, and R.sup.3 are defined in the specification, which are useful for the treatment of migraine and associate disorders.Type: GrantFiled: March 13, 1998Date of Patent: August 24, 1999Assignee: Eli Lilly and CompanyInventors: James E Fritz, Patric J Hahn, Stephen W Kaldor, Miles G Siegel, Yao-Chang Xu
-
Patent number: 5898123Abstract: A sealing device (30) is provided for sealing the interior of a pressure vessel such as the containment tube (20) of a separation device (8). The sealing device may comprises a detonation manifold (130, 230 or 330) having a body portion (31) having at least one initiation port (32) for receiving a secondary device such as initiation devices (15a, 15b) and at least one mounting boss (138 or 238) having an annular locking channel (162 or 262) along the side surface (138b or 238b) of the mounting boss. A locking collar (150 or 250) having an integral crimping band (158 or 258) which extends along and protrudes from an inner circumferential contact surface (151 or 251) of locking collar (150 or 250).Type: GrantFiled: May 1, 1997Date of Patent: April 27, 1999Assignee: The Ensign-Bickford CompanyInventors: James E. Fritz, John A. Graham, Steven L. Olson, Jon E. Rydberg
-
Patent number: 5846993Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: Agouron Pharmaceuticals, Inc.Inventors: Bruce A. Dressman, James E. Fritz, Stephen W. Kaldor, Vincent J. Kalish, Siegfried Heinz Reich, John H. Tatlock, Michael J. Rodriguez
-
Patent number: 5834467Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.Type: GrantFiled: June 7, 1995Date of Patent: November 10, 1998Assignee: Agouron Pharmaceuticals, Inc.Inventors: Vincent J. Kalish, Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriquez